About
Abologix is a biopharmaceutical company developing monoclonal antibodies targeting Junction Adhesion Molecule C (JAM-C) and Olfactomedin-like protein 3 (Olfml3) to create new cancer therapies focused on oncological indications.
Explore Abologix's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.